ATE235244T1 - Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten - Google Patents

Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten

Info

Publication number
ATE235244T1
ATE235244T1 AT99948982T AT99948982T ATE235244T1 AT E235244 T1 ATE235244 T1 AT E235244T1 AT 99948982 T AT99948982 T AT 99948982T AT 99948982 T AT99948982 T AT 99948982T AT E235244 T1 ATE235244 T1 AT E235244T1
Authority
AT
Austria
Prior art keywords
neurological
prevention
composition
treatment
pathopsychological
Prior art date
Application number
AT99948982T
Other languages
English (en)
Inventor
Herwig Buchholz
Jerzy D Meduski
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE235244T1 publication Critical patent/ATE235244T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT99948982T 1998-10-30 1999-10-13 Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten ATE235244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10623098P 1998-10-30 1998-10-30
PCT/EP1999/007688 WO2000025793A1 (en) 1998-10-30 1999-10-13 Compositions for the treatment and prevention of neurological and pathopsychological diseases

Publications (1)

Publication Number Publication Date
ATE235244T1 true ATE235244T1 (de) 2003-04-15

Family

ID=22310256

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99948982T ATE235244T1 (de) 1998-10-30 1999-10-13 Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten

Country Status (9)

Country Link
US (1) US6514973B1 (de)
EP (1) EP1124559B1 (de)
JP (1) JP2002528507A (de)
AT (1) ATE235244T1 (de)
AU (1) AU6202299A (de)
CA (1) CA2348390C (de)
DE (1) DE69906345T2 (de)
ES (1) ES2194513T3 (de)
WO (1) WO2000025793A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
US7591995B2 (en) 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
EP1334114A2 (de) 2000-10-25 2003-08-13 Mayo Foundation For Medical Education And Research Transcobalamin-bindende konjugate zur behandlung abnormaler zellulärer proliferation
US20020176881A1 (en) * 2001-01-26 2002-11-28 George Verlaan Rehydration composition
AU2002338230A1 (en) * 2001-03-26 2002-10-15 Giventis Gmbh Food item for increasing cognitive capacity
EP1302196A1 (de) * 2001-10-16 2003-04-16 Habinger, René, Ing. Mag. Intelligenzfördernde Zahncreme
CN100469361C (zh) * 2002-06-19 2009-03-18 纽迪希亚公司 治疗或预防哺乳动物遭受代谢作用压力时的分解代谢或刺激性合成代谢的方法及组合物
US7033612B2 (en) * 2003-01-03 2006-04-25 Kang David S Composition and method for treating age-related disorders
IL154318A (en) * 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
IL158139A0 (en) * 2003-09-25 2004-09-27 Enzymotec Ltd Stabilized formulations of phosphatidyl serine
US7935365B2 (en) * 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US8052992B2 (en) * 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20050130937A1 (en) * 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
EP1645276A1 (de) * 2004-10-08 2006-04-12 Wageningen Centre for Food Sciences Behandlung von neurodegenerativen Erkrankungen
EP1817023A4 (de) * 2004-11-16 2010-08-18 Limerick Biopharma Inc Verfahren und zusammensetzungen zur schmerzbehandlung
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
EP2249832A4 (de) 2008-01-30 2011-12-21 Agency Science Tech & Res Verfahren zur behandlung von fibrose und krebs mit imidazolium- und imidazolinium-verbindungen
US20110028513A1 (en) * 2008-03-31 2011-02-03 Lang Zhuo Method for treating neurological disorders with imidazolium and imidazolinium compounds
US8546104B2 (en) * 2008-08-07 2013-10-01 Lipogen Ltd. Processes for the preparation of phosphatide salts
CA2825428C (en) 2010-02-12 2022-06-14 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
WO2014018873A2 (en) * 2012-07-27 2014-01-30 Chemic Laboratories Inc. Compositions comprising folic acid derivatives. their preparations and methods of use
US11110113B2 (en) 2016-11-03 2021-09-07 Gentelon, Inc. Compositions and methods for treating depression
EP3886838A4 (de) 2018-11-30 2022-08-10 Beth Israel Deaconess Medical Center, Inc. Zusammensetzungen und verfahren zur verminderung von schweren thrombotischen ereignissen bei krebspatienten
EP4501315A1 (de) 2023-08-04 2025-02-05 Lesaffre et Compagnie Flüssige formulierungen von folaten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2041A1 (fr) * 1988-06-24 1990-05-30 Johannes Cornelius Str Andries Agents anti-atherogenic
IT1229517B (it) * 1989-01-31 1991-09-03 Bioresearch Spa Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
DE4117629A1 (de) 1991-05-29 1992-12-03 Max Planck Gesellschaft Phospatidylserine
ATE262799T1 (de) * 1996-01-31 2004-04-15 Univ South Alabama Lebensmittel und vitamin herstellungen mit natürlichem isomeren von reduzierten folaten
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
WO1999037155A1 (en) 1998-01-27 1999-07-29 Nutramax Laboratories, Inc. Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances

Also Published As

Publication number Publication date
EP1124559A1 (de) 2001-08-22
JP2002528507A (ja) 2002-09-03
EP1124559B1 (de) 2003-03-26
DE69906345T2 (de) 2004-02-12
CA2348390C (en) 2008-11-25
AU6202299A (en) 2000-05-22
CA2348390A1 (en) 2000-05-11
US6514973B1 (en) 2003-02-04
ES2194513T3 (es) 2003-11-16
DE69906345D1 (de) 2003-04-30
WO2000025793A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
DE69906345D1 (de) Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE60005560D1 (de) Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
LU91145I9 (de)
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
TR200102817T2 (tr) Antiinflamatuar ajanlar olarak faydalı bileşikler
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
ATE337316T1 (de) Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
DE60112330D1 (en) Pyrazolopyridinderivate
ATE221781T1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
ATE232874T1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
DE50004334D1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
DE69907418D1 (de) Verwendung von makroliden zur behandlung von glaukom
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
DE69838882D1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
ATE266027T1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties